LivingGLP1
Study S000881

A Double-Blind, Multicenter, Randomized Study Evaluating the Safety, and Pharmacokinetic/Pharmacodynamic Relationship in T2DMs Treated With 12 Weeks Injection of Polyethylene Glycol Loxenatide Add to Metformin

Registration

Registration
NCT01965509
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE2
Masking
QUADRUPLE
Status
COMPLETED
Enrollment
120
Start
2012-05
Primary completion
2013-08
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd.
Conditions
Type 2 Diabetes
Interventions
DRUG:PEX168 or placebo
Results posted
FALSE

Registered primary outcomes

  • To assess HbA1C levels after treatment [12 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.